TEDxBoston – Frank Reynolds
Changing the Face of Neuroscience
TEDxBigApple – Robert Langer
Biomaterials for the 21st Century
Ireland Ambassador Anne Andersen Awards Frank Reynolds the 2015 Taoiseach Award
“We’re Scientists and Engineers…we’re working to solve challenging problems.” – Robert S. Langer
Robert S Langer Founds Field of Drug Delivery Systems For Neuroscience
PixarBio’s co-founder Robert S. Langer, David H. Koch Institute Professor at MIT, has made key contributions to the field of neuroscience through drug delivery inventions utilizing new biomaterials for neuroprotection, localized delivery of drugs, and sustaining cell growth. One example is the Gliadel Wafer, approved by the FDA in Sep 1996 and co-invented by Robert S. Langer, ScD, and Henry Brem, M.D., Chief of Neurosurgery at Johns Hopkins University. The dime-sized wafer delivers chemotherapy directly to a site of the brain tumor removal. In 1996, the Gliadel Wafer became the first therapy in more than two decades to extend the lives of patients with the deadly brain cancer glioblastoma. (1) NIH Gliadel Wafer.
Frank Reynolds Leads Invention of InVivo Therapeutics Neuroscaffold, the first SCI treatment to restore function after SCI
In 2005, Frank Reynolds founded InVivo Therapeutics and invented a Neuroscaffold for SCI. Against all odds, Frank advanced the Neuroscaffold from rats to humans. He co-invented and led every iteration in the Neuroscaffold’s development and received US FDA approval to begin human studies. In Jan 2015, after just 90 days, the company reported first results, which were outstanding: patient control of bowel, control of bladder, hip muscle control, no adverse events. Patient enrollment is ongoing: www.clinicaltrials.gov
PixarBio Drives Non-Opiate Drugs Delivery Systems for Neurological Conditions
PixarBio Corp is a specialty Biotechnology company focused on pre-clinical and commercial development of new products that meet the needs of neurological clinicians and their patients. The company has developed a novel drug delivery platform to achieve sustained release of non-opiate drugs to treat post-operative, acute and chronic pain. Over the next 5 years, we will create a new clinical franchise in medicine around our pain product pipeline. As our drug delivery system for Parkinson’s disease, Epilepsy, and Spinal cord injury (SCI) evolves, PixarBio will be ready to scale.
Neuroscience will remain the most unknown frontier in science and medicine where the opportunity for biomaterial interventions appears endless.